Ionis Pharmaceuticals, Inc.
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipā¦ read more
Healthcare
Biotechnology
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$61.23
Price+3.17%
$1.88
1Y
Price
Market Cap
$9.760b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-29.3%
EBITDA Margin-29.3%
Net Profit Margin-69.2%
Free Cash Flow MarginRevenue
$944.237m
+3.2%
1y CAGR+3.3%
3y CAGR+5.2%
5y CAGREarnings
-$268.216m
+0.3%
1y CAGR-288.8%
3y CAGR-193.1%
5y CAGREPS
-$1.84
+1.6%
1y CAGR-279.3%
3y CAGR-186.0%
5y CAGRBook Value
$631.724m
$2.985b
Assets$2.353b
Liabilities$1.420b
DebtDebt to Assets
47.6%
-0.7x
Debt to EBITDAFree Cash Flow
-$569.175m
-2.7%
1y CAGR-799.9%
3y CAGR-512.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company